

Key Publications (Prof. J. Rüschoff)

MSI related

1. Validation and introduction of the MSI testing primer panel

Dietmaier W, ..., **Rüschoff J**. *Cancer Res* 57:4749-56, 1997

Adopted by NCI

Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, **Rüschoff J**, Fishel R, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 96:261-268, 2004

2. Providing the first evidence that **Aspirin is suppressing the MSI phenotype** in vitro

Rüschoff J et al. *PNAS* 95: 11301-6, 1998

confirmed by R. Fishel using COX2 specific NSAR drugs

McIlhatton MA, Tyler J, Burkholder S, **Rüschoff J**, Rigas B et al. *Cancer Res* 67:10966-75, 2007

Based on these data it has recently been shown that **Aspirin effectively suppresses tumors in Lynch Syndrome**

Burn J et al. *Lancet* 378: 2081-7, 2011

HER2 receptor analysis

1. HER2 testing within HERA trial as central reference lab:

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, ..., **Rüschoff J**, Suto T et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 353:1659-72, 2005


2. HER2 testing within ToGA trial (Herceptin in Gastric cancer) with validation of a specially adapted scoring system as proposed by our group (Hofmann et al. Histopathology 52:797-805, 2008)

Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, **Rüschoff J**, Kang Y-K for the ToGA Trial Investigators. Trastuzumab in combination with chemotherapy for the treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer. *Lancet* 376:687-97, 2010

Based on these experiences international recommendations for Her2 testing in gastric cancer have been published: **Rüschoff J** et al. *Mod Pathol* 25(5):637-650, 2012

Aktuelle Buchbeiträge

2013 (Band Mitherausgeber)



2014:

Kap. 3 Pathologie benigner und maligner Brustveränderungen

